nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—GNRHR—GPCRs, Other—GRM8—lung cancer	0.00319	0.0591	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—OXTR—lung cancer	0.0031	0.0574	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GRP—lung cancer	0.00148	0.0274	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—OXTR—lung cancer	0.00148	0.0274	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GNG11—lung cancer	0.00138	0.0256	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—lung cancer	0.00132	0.0245	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—OXTR—lung cancer	0.00132	0.0245	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG11—lung cancer	0.00124	0.0229	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—ANXA1—lung cancer	0.00109	0.0201	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GIPR—lung cancer	0.00106	0.0197	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—APP—lung cancer	0.00103	0.0191	CbGpPWpGaD
Nafarelin—Alopecia—Etoposide—lung cancer	0.000999	0.00106	CcSEcCtD
Nafarelin—Cerebrovascular accident—Methotrexate—lung cancer	0.000999	0.00106	CcSEcCtD
Nafarelin—Epistaxis—Docetaxel—lung cancer	0.000987	0.00104	CcSEcCtD
Nafarelin—Asthenia—Topotecan—lung cancer	0.000982	0.00104	CcSEcCtD
Nafarelin—Arthralgia—Gemcitabine—lung cancer	0.000981	0.00104	CcSEcCtD
Nafarelin—Myalgia—Gemcitabine—lung cancer	0.000981	0.00104	CcSEcCtD
Nafarelin—Chest pain—Gemcitabine—lung cancer	0.000981	0.00104	CcSEcCtD
Nafarelin—Alopecia—Paclitaxel—lung cancer	0.00098	0.00104	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.000978	0.0181	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.000978	0.0181	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—lung cancer	0.000972	0.018	CbGpPWpGaD
Nafarelin—Asthenia—Erlotinib—lung cancer	0.000972	0.00103	CcSEcCtD
Nafarelin—Mental disorder—Paclitaxel—lung cancer	0.000971	0.00103	CcSEcCtD
Nafarelin—Hepatic function abnormal—Doxorubicin—lung cancer	0.00097	0.00103	CcSEcCtD
Nafarelin—Pruritus—Topotecan—lung cancer	0.000968	0.00102	CcSEcCtD
Nafarelin—Oedema—Irinotecan—lung cancer	0.000966	0.00102	CcSEcCtD
Nafarelin—Malnutrition—Paclitaxel—lung cancer	0.000965	0.00102	CcSEcCtD
Nafarelin—Diarrhoea—Vinblastine—lung cancer	0.000964	0.00102	CcSEcCtD
Nafarelin—Dysgeusia—Etoposide—lung cancer	0.000964	0.00102	CcSEcCtD
Nafarelin—Pruritus—Erlotinib—lung cancer	0.000958	0.00101	CcSEcCtD
Nafarelin—Shock—Irinotecan—lung cancer	0.00095	0.001	CcSEcCtD
Nafarelin—Tension—Paclitaxel—lung cancer	0.000947	0.001	CcSEcCtD
Nafarelin—Dysgeusia—Paclitaxel—lung cancer	0.000945	0.000999	CcSEcCtD
Nafarelin—Rhinitis—Docetaxel—lung cancer	0.000942	0.000996	CcSEcCtD
Nafarelin—Oedema—Gemcitabine—lung cancer	0.000941	0.000994	CcSEcCtD
Nafarelin—Eye pain—Doxorubicin—lung cancer	0.000939	0.000992	CcSEcCtD
Nafarelin—Nervousness—Paclitaxel—lung cancer	0.000937	0.000991	CcSEcCtD
Nafarelin—Diarrhoea—Topotecan—lung cancer	0.000936	0.00099	CcSEcCtD
Nafarelin—Hyperhidrosis—Irinotecan—lung cancer	0.000934	0.000987	CcSEcCtD
Nafarelin—Dizziness—Vinblastine—lung cancer	0.000932	0.000985	CcSEcCtD
Nafarelin—Convulsion—Cisplatin—lung cancer	0.000931	0.000984	CcSEcCtD
Nafarelin—Urticaria—Vinorelbine—lung cancer	0.00093	0.000983	CcSEcCtD
Nafarelin—Mood swings—Methotrexate—lung cancer	0.000927	0.00098	CcSEcCtD
Nafarelin—Diarrhoea—Erlotinib—lung cancer	0.000927	0.000979	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—APP—lung cancer	0.000921	0.0171	CbGpPWpGaD
Nafarelin—Anorexia—Irinotecan—lung cancer	0.00092	0.000973	CcSEcCtD
Nafarelin—Myalgia—Cisplatin—lung cancer	0.000915	0.000967	CcSEcCtD
Nafarelin—Hyperhidrosis—Gemcitabine—lung cancer	0.000909	0.000961	CcSEcCtD
Nafarelin—Hot flush—Doxorubicin—lung cancer	0.000906	0.000958	CcSEcCtD
Nafarelin—Dizziness—Topotecan—lung cancer	0.000905	0.000957	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—GRM8—lung cancer	0.000904	0.0168	CbGpPWpGaD
Nafarelin—Increased appetite—Doxorubicin—lung cancer	0.000902	0.000954	CcSEcCtD
Nafarelin—Menopausal symptoms—Doxorubicin—lung cancer	0.000898	0.00095	CcSEcCtD
Nafarelin—Anorexia—Gemcitabine—lung cancer	0.000897	0.000948	CcSEcCtD
Nafarelin—Vomiting—Vinblastine—lung cancer	0.000896	0.000947	CcSEcCtD
Nafarelin—Dizziness—Erlotinib—lung cancer	0.000896	0.000947	CcSEcCtD
Nafarelin—Vertigo—Etoposide—lung cancer	0.000884	0.000935	CcSEcCtD
Nafarelin—Headache—Vinblastine—lung cancer	0.000883	0.000933	CcSEcCtD
Nafarelin—Oedema—Cisplatin—lung cancer	0.000877	0.000927	CcSEcCtD
Nafarelin—Insomnia—Irinotecan—lung cancer	0.000873	0.000923	CcSEcCtD
Nafarelin—Vomiting—Topotecan—lung cancer	0.00087	0.00092	CcSEcCtD
Nafarelin—Paraesthesia—Irinotecan—lung cancer	0.000867	0.000917	CcSEcCtD
Nafarelin—Vertigo—Paclitaxel—lung cancer	0.000867	0.000916	CcSEcCtD
Nafarelin—Cerebrovascular accident—Doxorubicin—lung cancer	0.000865	0.000914	CcSEcCtD
Nafarelin—Rash—Topotecan—lung cancer	0.000863	0.000912	CcSEcCtD
Nafarelin—Dermatitis—Topotecan—lung cancer	0.000862	0.000911	CcSEcCtD
Nafarelin—Vomiting—Erlotinib—lung cancer	0.000861	0.00091	CcSEcCtD
Nafarelin—Dyspnoea—Irinotecan—lung cancer	0.000861	0.00091	CcSEcCtD
Nafarelin—Headache—Topotecan—lung cancer	0.000857	0.000906	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000857	0.000906	CcSEcCtD
Nafarelin—Rash—Erlotinib—lung cancer	0.000854	0.000903	CcSEcCtD
Nafarelin—Dermatitis—Erlotinib—lung cancer	0.000853	0.000902	CcSEcCtD
Nafarelin—Palpitations—Paclitaxel—lung cancer	0.000853	0.000901	CcSEcCtD
Nafarelin—Convulsion—Etoposide—lung cancer	0.000853	0.000901	CcSEcCtD
Nafarelin—Insomnia—Gemcitabine—lung cancer	0.000851	0.000899	CcSEcCtD
Nafarelin—Headache—Erlotinib—lung cancer	0.000848	0.000897	CcSEcCtD
Nafarelin—Hyperhidrosis—Cisplatin—lung cancer	0.000848	0.000896	CcSEcCtD
Nafarelin—Paraesthesia—Gemcitabine—lung cancer	0.000845	0.000893	CcSEcCtD
Nafarelin—Asthenia—Vinorelbine—lung cancer	0.00084	0.000888	CcSEcCtD
Nafarelin—Decreased appetite—Irinotecan—lung cancer	0.000839	0.000887	CcSEcCtD
Nafarelin—Dyspnoea—Gemcitabine—lung cancer	0.000839	0.000886	CcSEcCtD
Nafarelin—Chest pain—Etoposide—lung cancer	0.000838	0.000886	CcSEcCtD
Nafarelin—Nausea—Vinblastine—lung cancer	0.000837	0.000885	CcSEcCtD
Nafarelin—Convulsion—Paclitaxel—lung cancer	0.000836	0.000884	CcSEcCtD
Nafarelin—Anorexia—Cisplatin—lung cancer	0.000836	0.000883	CcSEcCtD
Nafarelin—Affect lability—Doxorubicin—lung cancer	0.000834	0.000882	CcSEcCtD
Nafarelin—Alopecia—Docetaxel—lung cancer	0.00083	0.000878	CcSEcCtD
Nafarelin—Pruritus—Vinorelbine—lung cancer	0.000828	0.000876	CcSEcCtD
Nafarelin—Constipation—Irinotecan—lung cancer	0.000826	0.000873	CcSEcCtD
Nafarelin—Mental disorder—Docetaxel—lung cancer	0.000823	0.00087	CcSEcCtD
Nafarelin—Arthralgia—Paclitaxel—lung cancer	0.000822	0.000868	CcSEcCtD
Nafarelin—Chest pain—Paclitaxel—lung cancer	0.000822	0.000868	CcSEcCtD
Nafarelin—Myalgia—Paclitaxel—lung cancer	0.000822	0.000868	CcSEcCtD
Nafarelin—Malnutrition—Docetaxel—lung cancer	0.000818	0.000865	CcSEcCtD
Nafarelin—Decreased appetite—Gemcitabine—lung cancer	0.000818	0.000864	CcSEcCtD
Nafarelin—Nausea—Topotecan—lung cancer	0.000813	0.000859	CcSEcCtD
Nafarelin—Constipation—Gemcitabine—lung cancer	0.000804	0.00085	CcSEcCtD
Nafarelin—Nausea—Erlotinib—lung cancer	0.000804	0.00085	CcSEcCtD
Nafarelin—Mood swings—Doxorubicin—lung cancer	0.000803	0.000849	CcSEcCtD
Nafarelin—Diarrhoea—Vinorelbine—lung cancer	0.000801	0.000847	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—AVP—lung cancer	0.000801	0.0148	CbGpPWpGaD
Nafarelin—Dysgeusia—Docetaxel—lung cancer	0.000801	0.000847	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000799	0.000844	CcSEcCtD
Nafarelin—Dysuria—Methotrexate—lung cancer	0.000791	0.000836	CcSEcCtD
Nafarelin—Oedema—Paclitaxel—lung cancer	0.000788	0.000832	CcSEcCtD
Nafarelin—Paraesthesia—Cisplatin—lung cancer	0.000787	0.000832	CcSEcCtD
Nafarelin—Dyspnoea—Cisplatin—lung cancer	0.000782	0.000826	CcSEcCtD
Nafarelin—Dry skin—Doxorubicin—lung cancer	0.000777	0.000821	CcSEcCtD
Nafarelin—Hyperhidrosis—Etoposide—lung cancer	0.000776	0.000821	CcSEcCtD
Nafarelin—Shock—Paclitaxel—lung cancer	0.000775	0.000819	CcSEcCtD
Nafarelin—Dizziness—Vinorelbine—lung cancer	0.000774	0.000818	CcSEcCtD
Nafarelin—Anorexia—Etoposide—lung cancer	0.000766	0.000809	CcSEcCtD
Nafarelin—Decreased appetite—Cisplatin—lung cancer	0.000762	0.000806	CcSEcCtD
Nafarelin—Hyperhidrosis—Paclitaxel—lung cancer	0.000761	0.000805	CcSEcCtD
Nafarelin—Depression—Methotrexate—lung cancer	0.000752	0.000795	CcSEcCtD
Nafarelin—Anorexia—Paclitaxel—lung cancer	0.000751	0.000794	CcSEcCtD
Nafarelin—Gastritis—Doxorubicin—lung cancer	0.00075	0.000793	CcSEcCtD
Nafarelin—Muscular weakness—Doxorubicin—lung cancer	0.000748	0.00079	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—OXTR—lung cancer	0.000745	0.0138	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GRP—lung cancer	0.000745	0.0138	CbGpPWpGaD
Nafarelin—Vomiting—Vinorelbine—lung cancer	0.000744	0.000787	CcSEcCtD
Nafarelin—Rash—Vinorelbine—lung cancer	0.000738	0.00078	CcSEcCtD
Nafarelin—Dermatitis—Vinorelbine—lung cancer	0.000738	0.00078	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—lung cancer	0.000738	0.00078	CcSEcCtD
Nafarelin—Headache—Vinorelbine—lung cancer	0.000734	0.000775	CcSEcCtD
Nafarelin—Conjunctivitis—Methotrexate—lung cancer	0.000733	0.000775	CcSEcCtD
Nafarelin—Palpitations—Docetaxel—lung cancer	0.000723	0.000764	CcSEcCtD
Nafarelin—Paraesthesia—Etoposide—lung cancer	0.000721	0.000762	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.00072	0.0133	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000718	0.000758	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—lung cancer	0.000716	0.0133	CbGpPWpGaD
Nafarelin—Dyspnoea—Etoposide—lung cancer	0.000716	0.000757	CcSEcCtD
Nafarelin—Insomnia—Paclitaxel—lung cancer	0.000712	0.000753	CcSEcCtD
Nafarelin—Epistaxis—Methotrexate—lung cancer	0.000712	0.000752	CcSEcCtD
Nafarelin—Convulsion—Docetaxel—lung cancer	0.000709	0.000749	CcSEcCtD
Nafarelin—Paraesthesia—Paclitaxel—lung cancer	0.000707	0.000748	CcSEcCtD
Nafarelin—Dyspnoea—Paclitaxel—lung cancer	0.000702	0.000742	CcSEcCtD
Nafarelin—Decreased appetite—Etoposide—lung cancer	0.000698	0.000738	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—GNG11—lung cancer	0.000697	0.0129	CbGpPWpGaD
Nafarelin—Arthralgia—Docetaxel—lung cancer	0.000696	0.000736	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—lung cancer	0.000696	0.000736	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—lung cancer	0.000696	0.000736	CcSEcCtD
Nafarelin—Nausea—Vinorelbine—lung cancer	0.000695	0.000735	CcSEcCtD
Nafarelin—Asthenia—Irinotecan—lung cancer	0.000693	0.000732	CcSEcCtD
Nafarelin—Constipation—Etoposide—lung cancer	0.000687	0.000726	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—lung cancer	0.000685	0.000724	CcSEcCtD
Nafarelin—Decreased appetite—Paclitaxel—lung cancer	0.000685	0.000724	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.000682	0.0126	CbGpPWpGaD
Nafarelin—Asthenia—Gemcitabine—lung cancer	0.000675	0.000713	CcSEcCtD
Nafarelin—Constipation—Paclitaxel—lung cancer	0.000673	0.000712	CcSEcCtD
Nafarelin—Oedema—Docetaxel—lung cancer	0.000668	0.000706	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—lung cancer	0.000667	0.000705	CcSEcCtD
Nafarelin—Pruritus—Gemcitabine—lung cancer	0.000665	0.000703	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—lung cancer	0.000663	0.000701	CcSEcCtD
Nafarelin—Diarrhoea—Irinotecan—lung cancer	0.000661	0.000698	CcSEcCtD
Nafarelin—Shock—Docetaxel—lung cancer	0.000657	0.000694	CcSEcCtD
Nafarelin—Diarrhoea—Gemcitabine—lung cancer	0.000644	0.00068	CcSEcCtD
Nafarelin—Dizziness—Irinotecan—lung cancer	0.000639	0.000675	CcSEcCtD
Nafarelin—Urticaria—Etoposide—lung cancer	0.000638	0.000675	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—lung cancer	0.000636	0.000673	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—lung cancer	0.000635	0.000671	CcSEcCtD
Nafarelin—Asthenia—Cisplatin—lung cancer	0.000629	0.000665	CcSEcCtD
Nafarelin—Urticaria—Paclitaxel—lung cancer	0.000626	0.000661	CcSEcCtD
Nafarelin—Epistaxis—Doxorubicin—lung cancer	0.000616	0.000651	CcSEcCtD
Nafarelin—Vomiting—Irinotecan—lung cancer	0.000614	0.000649	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—lung cancer	0.000613	0.000648	CcSEcCtD
Nafarelin—Rash—Irinotecan—lung cancer	0.000609	0.000644	CcSEcCtD
Nafarelin—Dermatitis—Irinotecan—lung cancer	0.000608	0.000643	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000608	0.000643	CcSEcCtD
Nafarelin—Headache—Irinotecan—lung cancer	0.000605	0.000639	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—lung cancer	0.000604	0.000638	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GIPR—lung cancer	0.000601	0.0111	CbGpPWpGaD
Nafarelin—Diarrhoea—Cisplatin—lung cancer	0.0006	0.000634	CcSEcCtD
Nafarelin—Paraesthesia—Docetaxel—lung cancer	0.000599	0.000634	CcSEcCtD
Nafarelin—Alopecia—Methotrexate—lung cancer	0.000598	0.000633	CcSEcCtD
Nafarelin—Vomiting—Gemcitabine—lung cancer	0.000598	0.000632	CcSEcCtD
Nafarelin—Dyspnoea—Docetaxel—lung cancer	0.000595	0.000629	CcSEcCtD
Nafarelin—Mental disorder—Methotrexate—lung cancer	0.000593	0.000627	CcSEcCtD
Nafarelin—Rash—Gemcitabine—lung cancer	0.000593	0.000627	CcSEcCtD
Nafarelin—Dermatitis—Gemcitabine—lung cancer	0.000593	0.000626	CcSEcCtD
Nafarelin—Malnutrition—Methotrexate—lung cancer	0.00059	0.000623	CcSEcCtD
Nafarelin—Headache—Gemcitabine—lung cancer	0.000589	0.000623	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—lung cancer	0.000588	0.000621	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—PTHLH—lung cancer	0.000583	0.0108	CbGpPWpGaD
Nafarelin—Decreased appetite—Docetaxel—lung cancer	0.00058	0.000613	CcSEcCtD
Nafarelin—Dysgeusia—Methotrexate—lung cancer	0.000577	0.00061	CcSEcCtD
Nafarelin—Asthenia—Etoposide—lung cancer	0.000576	0.000609	CcSEcCtD
Nafarelin—Nausea—Irinotecan—lung cancer	0.000574	0.000606	CcSEcCtD
Nafarelin—Constipation—Docetaxel—lung cancer	0.000571	0.000603	CcSEcCtD
Nafarelin—Pruritus—Etoposide—lung cancer	0.000568	0.000601	CcSEcCtD
Nafarelin—Asthenia—Paclitaxel—lung cancer	0.000565	0.000597	CcSEcCtD
Nafarelin—Nausea—Gemcitabine—lung cancer	0.000559	0.000591	CcSEcCtD
Nafarelin—Vomiting—Cisplatin—lung cancer	0.000557	0.000589	CcSEcCtD
Nafarelin—Pruritus—Paclitaxel—lung cancer	0.000557	0.000589	CcSEcCtD
Nafarelin—Rash—Cisplatin—lung cancer	0.000553	0.000584	CcSEcCtD
Nafarelin—Dermatitis—Cisplatin—lung cancer	0.000552	0.000584	CcSEcCtD
Nafarelin—Diarrhoea—Etoposide—lung cancer	0.00055	0.000581	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—ANXA1—lung cancer	0.000548	0.0101	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GIPR—lung cancer	0.000546	0.0101	CbGpPWpGaD
Nafarelin—Diarrhoea—Paclitaxel—lung cancer	0.000539	0.00057	CcSEcCtD
Nafarelin—Dizziness—Etoposide—lung cancer	0.000531	0.000561	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.00053	0.00983	CbGpPWpGaD
Nafarelin—Vertigo—Methotrexate—lung cancer	0.00053	0.00056	CcSEcCtD
Nafarelin—Dizziness—Paclitaxel—lung cancer	0.000521	0.000551	CcSEcCtD
Nafarelin—Nausea—Cisplatin—lung cancer	0.000521	0.000551	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—APP—lung cancer	0.000519	0.00962	CbGpPWpGaD
Nafarelin—Alopecia—Doxorubicin—lung cancer	0.000518	0.000548	CcSEcCtD
Nafarelin—Mental disorder—Doxorubicin—lung cancer	0.000514	0.000543	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GRM8—lung cancer	0.000511	0.00947	CbGpPWpGaD
Nafarelin—Convulsion—Methotrexate—lung cancer	0.000511	0.00054	CcSEcCtD
Nafarelin—Vomiting—Etoposide—lung cancer	0.000511	0.00054	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—lung cancer	0.00051	0.00054	CcSEcCtD
Nafarelin—Rash—Etoposide—lung cancer	0.000506	0.000535	CcSEcCtD
Nafarelin—Dermatitis—Etoposide—lung cancer	0.000506	0.000535	CcSEcCtD
Nafarelin—Headache—Etoposide—lung cancer	0.000503	0.000532	CcSEcCtD
Nafarelin—Myalgia—Methotrexate—lung cancer	0.000502	0.000531	CcSEcCtD
Nafarelin—Chest pain—Methotrexate—lung cancer	0.000502	0.000531	CcSEcCtD
Nafarelin—Arthralgia—Methotrexate—lung cancer	0.000502	0.000531	CcSEcCtD
Nafarelin—Tension—Doxorubicin—lung cancer	0.000501	0.000529	CcSEcCtD
Nafarelin—Vomiting—Paclitaxel—lung cancer	0.000501	0.000529	CcSEcCtD
Nafarelin—Dysgeusia—Doxorubicin—lung cancer	0.0005	0.000528	CcSEcCtD
Nafarelin—Rash—Paclitaxel—lung cancer	0.000497	0.000525	CcSEcCtD
Nafarelin—Dermatitis—Paclitaxel—lung cancer	0.000496	0.000524	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—lung cancer	0.000496	0.000524	CcSEcCtD
Nafarelin—Headache—Paclitaxel—lung cancer	0.000493	0.000522	CcSEcCtD
Nafarelin—Asthenia—Docetaxel—lung cancer	0.000479	0.000506	CcSEcCtD
Nafarelin—Nausea—Etoposide—lung cancer	0.000477	0.000504	CcSEcCtD
Nafarelin—Pruritus—Docetaxel—lung cancer	0.000472	0.000499	CcSEcCtD
Nafarelin—Nausea—Paclitaxel—lung cancer	0.000468	0.000494	CcSEcCtD
Nafarelin—Hyperhidrosis—Methotrexate—lung cancer	0.000465	0.000492	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000464	0.0086	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRM8—lung cancer	0.000464	0.0086	CbGpPWpGaD
Nafarelin—Vertigo—Doxorubicin—lung cancer	0.000459	0.000485	CcSEcCtD
Nafarelin—Anorexia—Methotrexate—lung cancer	0.000459	0.000485	CcSEcCtD
Nafarelin—Diarrhoea—Docetaxel—lung cancer	0.000457	0.000483	CcSEcCtD
Nafarelin—Palpitations—Doxorubicin—lung cancer	0.000451	0.000477	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.000443	0.0082	CbGpPWpGaD
Nafarelin—Convulsion—Doxorubicin—lung cancer	0.000442	0.000468	CcSEcCtD
Nafarelin—Dizziness—Docetaxel—lung cancer	0.000441	0.000467	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000438	0.000463	CcSEcCtD
Nafarelin—Insomnia—Methotrexate—lung cancer	0.000435	0.00046	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—lung cancer	0.000435	0.000459	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—lung cancer	0.000435	0.000459	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—lung cancer	0.000435	0.000459	CcSEcCtD
Nafarelin—Paraesthesia—Methotrexate—lung cancer	0.000432	0.000457	CcSEcCtD
Nafarelin—Dyspnoea—Methotrexate—lung cancer	0.000429	0.000453	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—AXL—lung cancer	0.000425	0.00788	CbGpPWpGaD
Nafarelin—Vomiting—Docetaxel—lung cancer	0.000424	0.000449	CcSEcCtD
Nafarelin—Rash—Docetaxel—lung cancer	0.000421	0.000445	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—OXTR—lung cancer	0.000421	0.0078	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GRP—lung cancer	0.000421	0.0078	CbGpPWpGaD
Nafarelin—Dermatitis—Docetaxel—lung cancer	0.00042	0.000444	CcSEcCtD
Nafarelin—Decreased appetite—Methotrexate—lung cancer	0.000418	0.000442	CcSEcCtD
Nafarelin—Headache—Docetaxel—lung cancer	0.000418	0.000442	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—lung cancer	0.000417	0.00044	CcSEcCtD
Nafarelin—Shock—Doxorubicin—lung cancer	0.00041	0.000433	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—AVP—lung cancer	0.000404	0.00748	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Doxorubicin—lung cancer	0.000403	0.000426	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—lung cancer	0.000397	0.00042	CcSEcCtD
Nafarelin—Nausea—Docetaxel—lung cancer	0.000397	0.000419	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GNG11—lung cancer	0.000394	0.0073	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000393	0.00727	CbGpPWpGaD
Nafarelin—Urticaria—Methotrexate—lung cancer	0.000382	0.000404	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—OXTR—lung cancer	0.000382	0.00708	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GRP—lung cancer	0.000382	0.00708	CbGpPWpGaD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.00038	0.000401	CcSEcCtD
Nafarelin—Insomnia—Doxorubicin—lung cancer	0.000377	0.000398	CcSEcCtD
Nafarelin—Paraesthesia—Doxorubicin—lung cancer	0.000374	0.000395	CcSEcCtD
Nafarelin—Dyspnoea—Doxorubicin—lung cancer	0.000371	0.000393	CcSEcCtD
Nafarelin—Decreased appetite—Doxorubicin—lung cancer	0.000362	0.000383	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—GNG11—lung cancer	0.000358	0.00663	CbGpPWpGaD
Nafarelin—Constipation—Doxorubicin—lung cancer	0.000356	0.000377	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—ADCY1—lung cancer	0.000354	0.00656	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000353	0.00653	CbGpPWpGaD
Nafarelin—Asthenia—Methotrexate—lung cancer	0.000345	0.000365	CcSEcCtD
Nafarelin—Pruritus—Methotrexate—lung cancer	0.00034	0.00036	CcSEcCtD
Nafarelin—Urticaria—Doxorubicin—lung cancer	0.000331	0.00035	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—COL4A2—lung cancer	0.000331	0.00613	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PTHLH—lung cancer	0.000329	0.0061	CbGpPWpGaD
Nafarelin—Diarrhoea—Methotrexate—lung cancer	0.000329	0.000348	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GIPR—lung cancer	0.000322	0.00597	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ADCY1—lung cancer	0.000322	0.00596	CbGpPWpGaD
Nafarelin—Dizziness—Methotrexate—lung cancer	0.000318	0.000336	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PPP2R1B—lung cancer	0.000314	0.00581	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—ANXA1—lung cancer	0.00031	0.00574	CbGpPWpGaD
Nafarelin—Vomiting—Methotrexate—lung cancer	0.000306	0.000323	CcSEcCtD
Nafarelin—Rash—Methotrexate—lung cancer	0.000303	0.000321	CcSEcCtD
Nafarelin—Dermatitis—Methotrexate—lung cancer	0.000303	0.00032	CcSEcCtD
Nafarelin—Headache—Methotrexate—lung cancer	0.000301	0.000319	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SDC4—lung cancer	0.000301	0.00558	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTHLH—lung cancer	0.000299	0.00554	CbGpPWpGaD
Nafarelin—Asthenia—Doxorubicin—lung cancer	0.000299	0.000316	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	0.000295	0.00547	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—DUSP3—lung cancer	0.000295	0.00546	CbGpPWpGaD
Nafarelin—Pruritus—Doxorubicin—lung cancer	0.000295	0.000312	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—APP—lung cancer	0.000294	0.00544	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RHEB—lung cancer	0.000289	0.00536	CbGpPWpGaD
Nafarelin—Nausea—Methotrexate—lung cancer	0.000286	0.000302	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—lung cancer	0.000285	0.000301	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	0.000283	0.00524	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—ANXA1—lung cancer	0.000281	0.00521	CbGpPWpGaD
Nafarelin—Dizziness—Doxorubicin—lung cancer	0.000275	0.000291	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GRM8—lung cancer	0.000274	0.00508	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000273	0.00505	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	0.000269	0.00499	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—POMC—lung cancer	0.000268	0.00497	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—APP—lung cancer	0.000267	0.00494	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SKI—lung cancer	0.000266	0.00492	CbGpPWpGaD
Nafarelin—Vomiting—Doxorubicin—lung cancer	0.000265	0.00028	CcSEcCtD
Nafarelin—Rash—Doxorubicin—lung cancer	0.000263	0.000278	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—lung cancer	0.000262	0.000277	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—lung cancer	0.000261	0.00484	CbGpPWpGaD
Nafarelin—Headache—Doxorubicin—lung cancer	0.000261	0.000276	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	0.000254	0.00471	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—lung cancer	0.000247	0.000262	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	0.000234	0.00433	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PXN—lung cancer	0.000231	0.00427	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AVP—lung cancer	0.000228	0.00423	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GRP—lung cancer	0.000226	0.00418	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKR1C1—lung cancer	0.000226	0.00418	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—OXTR—lung cancer	0.000226	0.00418	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	0.000216	0.004	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GNG11—lung cancer	0.000211	0.00391	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—lung cancer	0.000208	0.00385	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AVP—lung cancer	0.000207	0.00384	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	0.000207	0.00383	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFC—lung cancer	0.000201	0.00373	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ADCY1—lung cancer	0.00019	0.00352	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SMARCA4—lung cancer	0.000185	0.00343	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PPP2R1B—lung cancer	0.000185	0.00343	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HSPB1—lung cancer	0.000179	0.00331	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTHLH—lung cancer	0.000177	0.00327	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ANXA1—lung cancer	0.000166	0.00308	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FLT1—lung cancer	0.000161	0.00298	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—lung cancer	0.000159	0.00295	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOTCH3—lung cancer	0.000157	0.00292	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APP—lung cancer	0.000157	0.00292	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGF9—lung cancer	0.000156	0.00289	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—POMC—lung cancer	0.000152	0.00281	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JUNB—lung cancer	0.000149	0.00276	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—lung cancer	0.000145	0.00268	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CD—lung cancer	0.00014	0.0026	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—POMC—lung cancer	0.000138	0.00255	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STK11—lung cancer	0.000135	0.00251	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6R—lung cancer	0.000134	0.00249	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FOXO3—lung cancer	0.000131	0.00242	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAP2K1—lung cancer	0.000128	0.00237	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CD—lung cancer	0.000127	0.00236	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AVP—lung cancer	0.000122	0.00227	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CB—lung cancer	0.000122	0.00226	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IGF1R—lung cancer	0.000118	0.00218	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—lung cancer	0.000117	0.00217	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HES1—lung cancer	0.000116	0.00214	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—RAF1—lung cancer	0.000114	0.0021	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IL2—lung cancer	0.000112	0.00208	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CB—lung cancer	0.000111	0.00205	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—lung cancer	0.000107	0.00197	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB3—lung cancer	0.000106	0.00196	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL2—lung cancer	0.000102	0.00189	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TERT—lung cancer	0.000101	0.00188	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—FGFR1—lung cancer	9.85e-05	0.00183	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HIF1A—lung cancer	9.7e-05	0.0018	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOA1—lung cancer	9.36e-05	0.00173	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KDR—lung cancer	9.28e-05	0.00172	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APC—lung cancer	8.55e-05	0.00158	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—lung cancer	8.55e-05	0.00158	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KIT—lung cancer	8.55e-05	0.00158	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—NRAS—lung cancer	8.55e-05	0.00158	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGF—lung cancer	8.45e-05	0.00157	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—MAPK3—lung cancer	8.19e-05	0.00152	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—POMC—lung cancer	8.14e-05	0.00151	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—BRAF—lung cancer	8.04e-05	0.00149	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6R—lung cancer	7.94e-05	0.00147	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CREBBP—lung cancer	7.93e-05	0.00147	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—lung cancer	7.79e-05	0.00144	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAP2K1—lung cancer	7.57e-05	0.0014	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CD—lung cancer	7.52e-05	0.00139	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—lung cancer	7.44e-05	0.00138	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—lung cancer	7.36e-05	0.00136	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—lung cancer	6.76e-05	0.00125	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MDM2—lung cancer	6.73e-05	0.00125	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—RAF1—lung cancer	6.71e-05	0.00124	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ERBB2—lung cancer	6.64e-05	0.00123	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CB—lung cancer	6.55e-05	0.00121	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MTOR—lung cancer	6.55e-05	0.00121	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—lung cancer	6.3e-05	0.00117	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—lung cancer	6.25e-05	0.00116	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—lung cancer	6.08e-05	0.00113	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASP3—lung cancer	6.03e-05	0.00112	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL2—lung cancer	6.02e-05	0.00111	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—IL6—lung cancer	5.99e-05	0.00111	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—lung cancer	5.86e-05	0.00109	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JUN—lung cancer	5.85e-05	0.00108	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—lung cancer	5.69e-05	0.00105	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CDKN1A—lung cancer	5.67e-05	0.00105	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—lung cancer	5.66e-05	0.00105	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—lung cancer	5.52e-05	0.00102	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EP300—lung cancer	5.4e-05	0.001	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SRC—lung cancer	5.25e-05	0.000972	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—lung cancer	5.11e-05	0.000947	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—lung cancer	5.06e-05	0.000938	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NRAS—lung cancer	5.05e-05	0.000935	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MAPK3—lung cancer	4.84e-05	0.000896	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—lung cancer	4.7e-05	0.000871	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—lung cancer	4.6e-05	0.000852	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—lung cancer	4.35e-05	0.000805	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—lung cancer	3.99e-05	0.00074	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—lung cancer	3.86e-05	0.000716	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—lung cancer	3.69e-05	0.000684	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—IL6—lung cancer	3.54e-05	0.000655	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—lung cancer	3.26e-05	0.000604	CbGpPWpGaD
